PipelineReview.com16h
Accord BioPharma Strengthens Pipeline Through Exclusive U.S. Licensing Agreement with Bio-Thera for BAT2506, a Proposed Golimumab Biosimilar
RALEIGH, NC, USA I 10, 2025 I Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas ...
PipelineReview.com16h
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
BRISBANE, Australia & INDIANAPOLIS, IN, USA I 10, 2025 I AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha ...
PipelineReview.com16h
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
INGELHEIM, Germany I 10, 2025 I Boehringer Ingelheim announced today that the FIBRONEER™-ILD trial met its primary endpoint, which was the ...
PipelineReview.com16h
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
PASADENA, CA, USA I 10 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement ...
PipelineReview.com16h
Orca Bio’s Orca-T® Meets Primary Endpoint in the Pivotal Precision-T Phase 3 Clinical Study for Hematologic Malignancies
Orca Bio to present efficacy and safety data with Orca-T compared to conventional allogeneic hematopoietic stem cell transplant (alloHSCT) at the 51st Annual ...
PipelineReview.com16h
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
OLX75016: A GWAS-derived therapeutic targeting MASH, liver fibrosis, and other cardiometabolic indications SEONGNAM, South Korea I 10, 2025 I OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading ...
PipelineReview.com23h
BioRay’s ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
SHANGHAI, China I 10, 2025 I On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products ...
PipelineReview.com23h
Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints
NEW TAIPEI CITY, Taiwan I February 9, 2025 I Caliway Biopharmaceuticals (TWSE-6919) announced today that CBL-514's second Phase 2b clinical study (CBL-0205), ...
PipelineReview.com23h
Bayer files for approval of extended 6-month treatment interval for Eylea™ 8 mg in the EU
Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...